introduct
acut
bronchiol
major
caus
acut
respiratori
distress
infant
solubl
receptor
advanc
glycat
endproduct
srage
biomark
pulmonari
damag
process
diagnost
prognost
valu
acut
respiratori
distress
syndrom
ard
rage
pathway
also
implic
pathogenesi
respiratori
diseas
like
asthma
valu
srage
level
acut
bronchiol
remain
underinvestig
materi
method
prospect
observ
analyt
studi
conduct
clermontferrand
univers
hospit
main
object
evalu
correl
serum
srage
clinic
sever
bronchiol
hospit
infant
age
year
analyz
correl
serum
srage
wainwright
score
shortterm
morbid
attribut
bronchiol
causal
virus
risk
recurr
wheez
year
studi
includ
infant
srage
level
significantli
lower
acut
bronchiol
patient
mean
pgml
control
pgml
p
correl
clinic
sever
correl
found
serum
srage
sever
score
respiratori
virus
recurr
wheez
year
serum
srage
level
neg
correl
age
r
p
conclus
serum
srage
level
decreas
acut
bronchiol
correl
diseas
sever
srage
level
ageadjust
infant
serum
srage
level
measur
set
acut
bronchiol
predict
recurr
wheez
blood
urin
biomark
infant
lower
respiratori
tract
infect
recurr
wheez
solubl
receptor
advanc
glycat
endproduct
role
rage
lung
diseas
asthma
allerg
airway
inflamm
acut
respiratori
distress
syndrom
ard
bronchopulmonari
dysplasia
solubl
rage
srage
repres
total
pool
solubl
form
rage
measur
extracellular
compart
eg
biolog
fluid
srage
lack
transmembran
domain
altern
splice
mechan
proteolyt
cleavag
includ
extracellular
domain
mrage
thu
srage
act
decoy
prevent
activ
mrage
ligand
proinflammatori
action
figur
sever
human
studi
argu
srage
marker
pulmonari
damag
process
adult
children
plasma
srage
associ
sever
prognosi
ard
srage
measur
may
also
valuabl
assess
sever
asthma
children
howev
valu
measur
srage
acut
bronchiol
poorli
investig
date
design
studi
investig
whether
serum
srage
could
marker
sever
infant
acut
bronchiol
predictor
risk
develop
recurr
wheez
bronchiol
diagnos
presenc
recent
histori
upper
figur
srage
aris
altern
splice
mechan
proteolyt
cleavag
srage
includ
extracellular
domain
mrage
extracellular
compart
srage
act
decoy
captur
mrage
receptor
ligand
block
proinflammatori
signal
respiratori
tract
infect
follow
onset
respiratori
distress
cough
tachypnea
retract
auscultatori
find
diffus
crackl
wheez
accord
intern
recommend
diagnosi
manag
acut
bronchiol
admiss
criteria
base
french
nation
guidelin
pediatr
intens
care
unit
picu
need
case
sign
exhaust
listless
decreas
respiratori
effort
recurr
apnea
failur
maintain
adequ
oxygen
satur
despit
oxygen
supplement
infant
born
week
amenorrhea
infant
cystic
fibrosi
bronchopulmonari
dysplasia
suspect
primari
ciliari
dyskinesia
congenit
heart
diseas
immun
defici
acut
renal
failur
exclud
infant
age
year
attend
anesthesia
consult
ahead
plan
surgic
intervent
enrol
control
group
health
statu
evalu
complet
medic
checkup
clinic
questionnair
children
previou
histori
pulmonari
diseas
histori
wheez
cardiopulmonari
diseas
chronic
pulmonari
diseas
prematur
infecti
process
exclud
case
control
enrol
provid
parent
oral
written
inform
collect
written
consent
clinic
sever
assess
inclus
use
wainwright
clinic
score
base
respiratori
effort
oxygen
satur
respiratori
rate
score
defin
three
stage
sever
nonsever
bronchiol
moder
sever
data
collect
includ
person
medic
histori
perinat
atop
histori
immedi
complic
relat
acut
bronchiol
bacteri
superinfect
pneumothorax
atelectasi
use
oral
inhal
corticosteroid
immedi
morbid
mortal
assess
use
data
collect
hospit
length
hospit
stay
use
durat
enter
nutrit
parenter
rehydr
need
oxygen
therapi
respiratori
support
continu
posit
airway
pressur
cpap
bilevel
posit
airway
pressur
bipap
invas
mechan
ventil
incid
superinfect
diagnos
biolog
radiolog
radiograph
featur
ventil
disord
radiologicallydocu
ga
effus
bronchospasm
use
inhal
betaagonist
corticosteroid
death
famili
phonesurvey
day
year
inclus
collect
data
recurr
wheez
bronchiol
asthma
wheez
without
consult
use
respiratori
treatment
oral
corticosteroid
respiratori
physiotherapi
hospit
admiss
respiratori
reason
diagnosi
recurr
wheez
alreadi
establish
anoth
pediatrician
base
occurr
third
bronchiol
episod
prescript
longterm
treatment
respiratori
symptom
admiss
hospit
blood
sampl
ml
sampl
venipunctur
tube
lithium
heparin
urin
ml
sampl
z
tube
without
addit
collect
pocket
compress
layer
blood
urin
sampl
immedi
centrifug
rpm
min
supernat
kept
frozen
analysi
srage
level
measur
duplic
use
purposedesign
commerciallyavail
elisa
kit
rage
quantikin
r
system
minneapoli
mn
manufacturerst
limit
detect
pgml
personnel
respons
perform
srage
assay
knowledg
clinic
set
nasopharyng
swab
sampl
collect
aspir
nasal
secret
viral
analysi
carri
use
enzymat
immunoassay
chromatographi
rsv
antigen
detect
molecular
biolog
method
includ
revers
transcriptionpolymeras
chain
reaction
rtpcr
rsv
rhinoviru
infant
admit
gener
pediatr
shortstay
unit
multiplex
pcr
panel
adenoviru
coronaviru
metapneumoviru
enterovirusrhinoviru
influenza
b
parainfluenza
viru
rsv
bordetella
pertussi
chlamydia
pneumonia
mycoplasma
pneumonia
infant
admit
intens
care
unit
rhinoviru
strain
genotyp
chest
xray
perform
respiratori
complic
andor
recurr
wheez
suspect
statist
analys
perform
use
stata
statacorp
colleg
station
tx
pvalu
twosid
consid
statist
signific
data
express
frequenc
percentag
qualit
variabl
mean
standard
deviat
median
interquartil
interv
quantit
variabl
casecontrol
analysi
perform
use
test
ninetythre
case
includ
mainli
young
infant
median
age
month
first
n
mild
n
episod
acut
bronchiol
case
moder
episod
present
sever
acut
bronchiol
accord
wainwright
score
median
hospit
stay
day
significantli
associ
wainwright
score
median
stay
day
nonsever
bronchiol
day
moder
bronchiol
day
sever
bronchiol
p
twentyf
infant
admit
intens
care
unit
includ
eight
case
admit
apnea
tabl
none
develop
ard
fiftyf
percent
case
firstdegre
famili
histori
atop
diseas
famili
histori
asthma
fifteen
percent
case
person
histori
atop
diseas
eczema
cow
milk
protein
allergi
recurr
wheez
studi
inclus
three
case
enrol
third
episod
one
case
includ
enrol
fourth
episod
bronchial
crackl
found
children
eight
percent
treat
betaagonist
inhal
corticosteroid
one
year
inclus
parent
case
respond
phone
survey
infant
develop
recurr
wheez
thirtytwo
control
includ
median
age
month
p
agecompar
case
boy
gender
differ
case
control
popul
statist
signific
p
differ
case
control
group
birth
term
p
weight
p
mean
serum
srage
sd
pgml
infant
acut
bronchiol
mean
serum
srage
correl
neg
age
r
p
highest
rate
found
among
younger
infant
tabl
correl
confirm
multivari
analysi
p
mean
serum
srage
sd
pgml
control
statist
signific
correl
age
r
p
tabl
serum
srage
level
significantli
higher
control
infant
acut
bronchiol
p
even
multivari
adjust
includ
age
covari
p
figur
multivari
analysi
show
lower
attrit
rate
point
case
addit
month
life
lower
attrit
rate
point
srage
level
differ
accord
causal
viru
srage
undetect
urin
sampl
patient
complic
bacteri
superinfect
p
atelectasi
p
similar
srage
level
main
object
studi
investig
associ
serum
srage
sever
acut
bronchiol
bacteri
superinfect
could
also
surpris
addit
correl
srage
rate
sever
evalu
morbid
data
total
hospit
stay
type
hospit
unit
need
respiratori
support
respiratori
support
durat
morbid
data
probabl
even
reliabl
wainwright
score
sinc
evalu
inclus
case
low
number
sever
case
could
bia
studi
seem
true
accord
distribut
popul
establish
wainwright
score
howev
observ
sever
hospit
data
case
admit
intens
care
unit
repres
real
sever
case
acut
bronchiol
explain
low
serum
srage
level
acut
bronchiol
two
physiopatholog
hypothes
made
suppos
high
srage
level
could
exert
benefici
antiinflammatori
effect
block
proinflammatori
axi
rage
srage
consid
blocker
inflammatori
cascad
could
consum
bind
proinflammatori
rage
ligand
order
control
inflamm
gener
viral
aggress
could
partli
explain
lower
srage
level
bronchiol
group
control
group
hand
may
hypothes
constitut
lower
srage
level
predispos
acut
bronchiol
sever
episod
result
first
observ
studi
must
confirm
larger
multicentr
popul
conclud
physiopatholog
model
cohort
studi
birth
measur
srage
kinet
could
arbitr
predispos
role
postev
consequ
lower
srage
level
acut
bronchiol
regardless
relationship
srage
sever
acut
bronchiol
interpret
without
consider
age
inde
singular
featur
srage
level
infanc
broad
variabl
age
due
pulmonari
matur
alveolar
process
last
month
srage
level
decreas
progress
bronchoalveolar
fluid
balf
serum
week
amenorrhea
birth
birth
adulthood
find
confirm
well
describ
figur
unfortun
obtain
data
control
infant
one
month
old
studi
may
underpow
detect
signific
neg
correl
serum
srage
age
control
major
variat
factor
srage
level
could
explain
discrep
studi
result
et
al
studi
show
pattern
opposit
higher
serum
srage
level
sever
acut
bronchiol
control
differ
pattern
seem
like
due
controlgroup
factor
et
al
control
older
target
popul
acut
bronchiol
averag
age
year
largecohort
studi
found
serum
srage
level
lower
infant
acut
bronchiol
without
acut
bronchiol
whatev
age
final
studi
show
differ
srage
level
accord
acut
bronchiol
sever
even
adjust
age
studi
age
major
confound
factor
acut
bronchiol
sever
sever
youngest
srage
physiolog
level
higher
rate
found
youngest
age
adjust
srage
rate
seem
relat
presenc
absenc
acut
bronchiol
rather
sever
long
term
srage
level
correl
risk
recurr
wheez
year
